HB795, titled the “Pregnancy Is Not an Illness Act of 2025,” would bar the Department of Health and Human Services, including the Food and Drug Administration, from treating pregnancy as an illness when approving abortion drugs or when imposing or maintaining risk evaluation and mitigation strategies (REMS) for those drugs. The bill is aimed at the federal drug-approval framework under the Federal Food, Drug, and Cosmetic Act, specifically section 505 and section 505-1.
The bill also contains a retroactive provision that would nullify any “prohibited approval” of an abortion drug, defined as an approval that relied in whole or in part on treating pregnancy as an illness. It expressly includes the existing approval of mifepristone as of the day before enactment, meaning the bill would attempt to invalidate that approval if enacted. In practical terms, the measure would directly affect FDA authority over abortion medication approvals and related safety restrictions.
Impact
If enacted, HB795 would amend the practical operation of federal drug-approval law by restricting how HHS and FDA may justify approvals and safety controls for abortion drugs. It would specifically target approvals under the Federal Food, Drug, and Cosmetic Act and could nullify existing approvals, including mifepristone, if they are deemed to have relied on the treatment of pregnancy as an illness. The bill would therefore affect FDA regulatory authority, abortion drug manufacturers, healthcare providers prescribing such drugs, and patients seeking medication abortion.
Sentiment
No committee transcript or vote data is available, so there is no recorded debate or roll-call sentiment in the provided materials. Based on the bill text and sponsorship, the measure appears to reflect strong anti-abortion sentiment and a desire to constrain federal approval of abortion medications. The introduction by multiple Republican members suggests support among abortion opponents, while the absence of recorded committee action beyond referral means broader legislative sentiment cannot yet be measured from the provided record.
Contention
The central point of contention is the bill’s premise that pregnancy should not be treated as an illness in the context of abortion drug approvals, which directly challenges FDA’s existing regulatory approach. Supporters are likely to argue that the bill prevents misuse of medical classifications to justify abortion drug approvals, while opponents would likely view it as an attack on FDA authority, scientific review, and access to medication abortion. The explicit inclusion of mifepristone’s existing approval makes the bill especially controversial because it would reach beyond future approvals and attempt to invalidate a currently approved drug.